NAARDEN, The Netherlands and MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical...
-- New patent extends patent term for obicetrapib until July 2043 -- NAARDEN, the Netherlands and MIAMI, June 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or...
-- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib's impact on key lipid and lipoprotein biomarkers -- -- On track to report topline...
NAARDEN, the Netherlands and MIAMI, April 09, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or œNewAmsterdam or the œCompany), a late-stage, clinical biopharmaceutical...
NewAmsterdam #Doses First Patient in Phase 3 Evaluating Obicetrapib & Ezetimibe
-- Observed reductions of 11% and 12% in 24- and 27-hydroxycholesterol in cerebrospinal fluid (œCSF), respectively, indicating potential improvement of cholesterol metabolism in the brain -- --...
Obicetrapib as a treatment for reducing cholesterol levels has potential to be the first cholesteryl ester transfer protein (CETP) inhibitor to advance to clinical practice, data and analytics company GlobalData has reported. This forecast is based on positive data from NewAmsterdam Pharma’s Phase II ROSE2 trial evaluating obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy.
Achieved Primary Endpoint with Statistically Significant 45.8% Median Reduction in LDL-C (p < 0.0001) in patients treated with 10mg obicetrapib-- -- 29.7% Median Reduction in Apo B and 37.0%...
Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p<0.0001) – – 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of <55...
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia